Integra LifeSciences Holdings Beats Expectations But Takes A Step Back Anyway
Integra LifeSciences Holdings (NAS: IART) reported earnings on Aug. 1. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended June 30 (Q2), Integra LifeSciences Holdings met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue dropped slightly. Non-GAAP earnings per share dropped significantly. GAAP earnings per share dropped significantly.
Margins shrank across the board.
Integra LifeSciences Holdings chalked up revenue of $205.5 million. The 15 analysts polled by S&P Capital IQ wanted to see sales of $207.5 million on the same basis. GAAP reported sales were 2.2% lower than the prior-year quarter's $210.2 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.
EPS came in at $0.60. The 15 earnings estimates compiled by S&P Capital IQ forecast $0.53 per share. Non-GAAP EPS of $0.60 for Q2 were 19% lower than the prior-year quarter's $0.74 per share. GAAP EPS of $0.12 for Q2 were 60% lower than the prior-year quarter's $0.30 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.
For the quarter, gross margin was 59.6%, 490 basis points worse than the prior-year quarter. Operating margin was 3.9%, 910 basis points worse than the prior-year quarter. Net margin was 1.7%, 240 basis points worse than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $214.6 million. On the bottom line, the average EPS estimate is $0.71.
Next year's average estimate for revenue is $843.6 million. The average EPS estimate is $2.49.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 151 members out of 163 rating the stock outperform, and 12 members rating it underperform. Among 60 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 57 give Integra LifeSciences Holdings a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Integra LifeSciences Holdings is hold, with an average price target of $40.50.
Is Integra LifeSciences Holdings the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Integra LifeSciences Holdings to My Watchlist.
The article Integra LifeSciences Holdings Beats Expectations But Takes A Step Back Anyway originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.